Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, is dedicated to developing innovative therapies for rare diseases. Founded in 2002, the company has made significant strides in the industry, particularly in the treatment of sickle cell disease. Emmaus is renowned for its flagship product, Endari, which is the first FDA-approved treatment specifically for patients aged five and older with this condition. The unique formulation of L-glutamine in Endari helps reduce the frequency of painful crises and hospitalisations, setting it apart in the market. With a strong commitment to research and development, Emmaus Life Sciences continues to expand its operational reach, aiming to improve the quality of life for patients globally. The company’s dedication to addressing unmet medical needs positions it as a notable player in the biopharmaceutical landscape.
DitchCarbon Score
How does Emmaus Life Sciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Emmaus Life Sciences, Inc.'s score of 23 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Emmaus Life Sciences, Inc.'s reported carbon emissions
Emmaus Life Sciences, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is unclear how the company is addressing its carbon footprint or contributing to climate action. In the absence of detailed information, it is essential to monitor their future disclosures for any developments regarding their climate commitments and sustainability practices.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Emmaus Life Sciences, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
